Press Releases

New research to be presented at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago shows that a previously untested combination of a monoclonal antibody-drug conjugate with a common chemotherapy agent has a high complete-response rate in children and young adults with relapsed or refractory Hodgkin lymphoma. This cooperative-group clinical trial, Children’s Oncology Group study AHOD1221 (NCT01780662), was led by Kara Kelly, MD, Waldemar J. Kaminski Endowed Chair of Pediatrics at Roswell Park Comprehensive Cancer Center.

Researchers at Roswell Park Comprehensive Cancer Center have garnered $6.4 million in new grant funding to support important investigations, including an award of more than $2 million from the National Cancer Institute to Yuesheng Zhang, MD, PhD, Professor of Oncology in the Department of Pharmacology & Therapeutics, for his research to improve colorectal cancer treatment.

BUFFALO, N.Y. — It’s estimated that there are more than 15.5 million cancer survivors living in the United States, with that number expected to rise dramatically over the next two decades.

A new study led by researchers at Roswell Park Comprehensive Cancer Center establishes a connection between a sedentary lifestyle and risk of developing kidney or bladder cancer. The findings extend a line of inquiry that has already revealed a connection between chronic inactivity and heightened risk for both ovarian and cervical cancer, and also highlight the possibility of reducing risk for some cancers by increasing physical activity.

Roswell Park Comprehensive Cancer Center has been named to Forbes’ 2017 list of America’s Best Employers. The Buffalo, N.Y., comprehensive cancer center was ranked 169th on the media organization’s list of 300 Best Midsize Employers across 25 industries.

More than 10 nursing teams from Roswell Park Comprehensive Cancer Center were invited to present their research at the 42nd Annual Congress of the Oncology Nursing Society (ONS) May 4–7, 2017, in Denver, Colorado.

In a new study, Roswell Park Comprehensive Cancer Center researchers have demonstrated that an approach shown to improve outcomes for patients receiving colorectal surgery is just as effective in patients requiring many other abdominal and pelvic operations.

Pawel Kalinski, MD, PhD, has joined Roswell Park Comprehensive Cancer Center as Vice Chair for Translational Research within the Department of Medicine and Director of Cancer Vaccine and Dendritic Cell Therapies within the Center for Immunotherapy.

Patients who expressed the tumor antigen NY-ESO-1 had more aggressive cancers and were more likely to die early from their disease, according to a large study conducted by Roswell Park Comprehensive Cancer Center researchers and published online ahead of print in the journal Gynecologic Oncology.